Market by Therapeutics and Diagnostics and Regional Outlook | Forecast 2021-2028
The detailed analysis of the Alzheimer’s disease therapeutics and diagnostics market shows that, in terms of revenue, the industry is estimated to grow at a CAGR of 5.56% during the forecasting years 2021-2028. It was valued at $6585.9 million in 2020, and is expected to amount to $10149.5 million by 2028.
Alzheimer’s
is a degenerative, progressive ailment that attacks the brain’s neurons,
resulting in memory loss, language skills, thinking, and behavioral changes.
The
increasing investments in biomarkers for drug development and the early detection
of Alzheimer’s disease can lead to higher adoption rates of biomarker-based
diagnostics as well as the development of new therapeutics, which, in turn, have
fueled the Alzheimer’s Disease Therapeutics and Diagnostics market growth
worldwide.
During
the outbreak of COVID-19, some clinical trials related to Alzheimer’s disease
were being postponed due to the fear of contamination. A proportion of people
with dementia are in care homes. They tend to be older and have multiple other
health conditions. Currently, a number of drugs are in the late pipeline stages
of drug development for AD. In fact, there are more candidates than ever, and
there are many novel drug applicants aimed at addressing the actual
pathological cause of AD, which the currently marketed drugs are unable to
address.
The
study aims to get an overview of the Alzheimer’s disease therapeutics and
diagnostics market in terms of various factors. Within this report, the key
insight and the market summary regarding the Alzheimer’s disease therapeutics
and diagnostics industry have been discussed. Also, the impact of COVID-19 on the
Alzheimer’s disease therapeutics and diagnostics market, key buying impact
analysis, industry components, different phases of Alzheimer’s disease, market
attractiveness index, vendor scorecard, and key strategic developments have been
studied in detail.
Factors
like the growing prevalence of dementia in the aged population, the growing
cases of Alzheimer’s disease in developed countries, the launch of new drugs,
and the prevailing clinical trials are driving the market growth. However, the
industry is facing restraints, such as stringent regulations associated with drug
development & clinical trials and failure of the late-stage drugs to induce
significant improvement in symptoms, which are obstructing the Alzheimer’s
disease therapeutics and diagnostics industry’s growth.
Key
opportunities like the emerging novel diagnostic technologies for the treatment
of Alzheimer’s disease can be leveraged by the industry to reach the projected
growth.
Geographies covered in the Alzheimer’s disease therapeutics
and diagnostics market by region are:
• North America: The United States and
Canada
• Europe: Russia, Spain, the United
Kingdom, Germany, France, Italy, and Rest of Europe
• Asia-Pacific: Australia & New
Zealand, Japan, India, ASEAN countries, South Korea, China, and Rest of
Asia-Pacific
• Latin America: Mexico, Brazil, and
Rest of Latin America
• Middle East and Africa: The United
Arab Emirates, Turkey, Saudi Arabia, South Africa, and Rest of Middle East
& Africa
The global Alzheimer’s disease therapeutics and diagnostics
market has been segmented as follows:
• By
Therapeutics and Diagnostics
o Therapeutics
• Therapeutics
by Drugs
o Marketed Drugs
o Pipeline Drugs
• Therapeutics
by Disease Stage
o Late-Stage: Severe AD
o Early/Middle Stage: Mild to Moderate
AD
o Prodromal Stage
• Therapeutics
by Generic and Branded
o Branded
o Generic
o Diagnostics
• Lumbar Puncture Test
• Positron Emission Tomography
• Electroencephalography
• Magnetic Resonance Imaging
• Computed Tomography
• Blood Test
• Other Diagnostics
The
key players engaged in the Alzheimer’s disease therapeutics and diagnostics
market are Novartis AG, GE Healthcare, Zydus Cadila, Lupin Limited, Merck &
Co Inc, Siemens Healthineers AG, Baxter International Inc, Eisai Co Ltd, Eli
Lilly & Company, Amarantus Bioscience Holdings Inc, Johnson & Johnson,
F Hoffmann La Roche, Cognoptix Inc, Sun Pharmaceuticals Industries Ltd, Luye
Pharma Group, Allergan Plc acquired by Abbvie, Teva Pharmaceutical Industries
Limited, Biogen Inc, Pfizer Inc, and PeopleBio Co.
The
strategic analysis for each of these companies has been covered in detail. The global
Alzheimer’s disease therapeutics and diagnostics market by company profile
helps dive into data about the key market players in this industry.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. KEY
INSIGHTS
2.2. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.3. PORTER’S
FIVE FORCES MODEL
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. COMPETITIVE
RIVALRY
2.4. KEY
BUYING IMPACT ANALYSIS
2.5. INDUSTRY
COMPONENTS
2.6. DIFFERENT
PHASES OF ALZHEIMER’S DISEASE
2.7. MARKET
ATTRACTIVENESS INDEX
2.8. VENDOR
SCORECARD
2.9. KEY
STRATEGIC DEVELOPMENTS
2.9.1. CONTRACTS
& PARTNERSHIPS
2.9.2. DIVESTITURES
BUSINESS EXPANSIONS & DIVESTITURES
2.9.3. ACQUISITIONS
& MERGERS
2.9.4. NEW
PRODUCT LAUNCHES
2.10. MARKET
DRIVERS
2.10.1. GROWING
DEMENTIA AMONG THE ELDERLY
2.10.2. HIGH
PREVALENCE OF ALZHEIMER’S DISEASE IN DEVELOPED COUNTRIES
2.10.3. LAUNCH
OF NEW DRUGS AND THE PREVAILING CLINICAL TRIALS RESULTING IN ROBUST MARKET GROWTH
2.11. MARKET
CHALLENGES
2.11.1. STRINGENT
REGULATIONS ASSOCIATED WITH DRUG DEVELOPMENT AND CLINICAL TRIALS
2.11.2. FAILURE
OF THE LATE-STAGE DRUGS TO INDUCE SIGNIFICANT IMPROVEMENT IN SYMPTOMS
2.12. MARKET
OPPORTUNITIES
2.12.1. EMERGING
NOVEL DIAGNOSTIC TECHNOLOGIES FOR ALZHEIMER’S DISEASE TREATMENT
3. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS AND
DIAGNOSTICS
3.1. THERAPEUTICS
3.1.1. THERAPEUTICS
BY DRUGS
3.1.1.1. MARKETED
DRUGS
3.1.1.2. PIPELINE
DRUGS
3.1.2. THERAPEUTICS
BY DISEASE STAGE
3.1.2.1. LATE
STAGE: SEVERE AD
3.1.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.1.2.3. PRODROMAL
STAGE
3.1.3. THERAPEUTICS
BY GENERIC AND BRANDED
3.1.3.1. BRANDED
3.1.3.2. GENERIC
3.2. DIAGNOSTICS
3.2.1. LUMBAR
PUNCTURE TEST
3.2.2. POSITRON
EMISSION TOMOGRAPHY
3.2.3. ELECTROENCEPHALOGRAPHY
3.2.4. MAGNETIC
RESONANCE IMAGING
3.2.5. COMPUTED
TOMOGRAPHY
3.2.6. BLOOD
TEST
3.2.7. OTHER
DIAGNOSTICS
4. GLOBAL
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK
4.1. NORTH
AMERICA
4.1.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.1.1.1. THERAPEUTICS
MARKET BY DRUGS
4.1.1.2. THERAPEUTICS
MARKET BY DISEASE STAGE
4.1.1.3. THERAPEUTICS
MARKET BY GENERIC AND BRANDED
4.1.1.4. DIAGNOSTICS
MARKET BY TYPE
4.1.2. COUNTRY
ANALYSIS
4.1.2.1. THE
UNITED STATES
4.1.2.2. CANADA
4.2. EUROPE
4.2.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.2.1.1. THERAPEUTICS
MARKET BY DRUGS
4.2.1.2. THERAPEUTICS
MARKET BY DISEASE STAGE
4.2.1.3. THERAPEUTICS
MARKET BY GENERIC AND BRANDED
4.2.1.4. DIAGNOSTICS
MARKET BY TYPE
4.2.2. COUNTRY
ANALYSIS
4.2.2.1. UNITED
KINGDOM
4.2.2.2. FRANCE
4.2.2.3. GERMANY
4.2.2.4. ITALY
4.2.2.5. RUSSIA
4.2.2.6. SPAIN
4.2.2.7. REST
OF EUROPE
4.3. ASIA-PACIFIC
4.3.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.3.1.1. THERAPEUTICS
MARKET BY DRUGS
4.3.1.2. THERAPEUTICS
MARKET BY DISEASE STAGE
4.3.1.3. THERAPEUTICS
MARKET BY GENERIC AND BRANDED
4.3.1.4. DIAGNOSTICS
MARKET BY TYPE
4.3.2. COUNTRY
ANALYSIS
4.3.2.1. CHINA
4.3.2.2. INDIA
4.3.2.3. JAPAN
4.3.2.4. AUSTRALIA
& NEW ZEALAND
4.3.2.5. SOUTH
KOREA
4.3.2.6. ASEAN
COUNTRIES
4.3.2.7. REST
OF ASIA-PACIFIC
4.4. LATIN
AMERICA
4.4.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.4.1.1. THERAPEUTICS
MARKET BY DRUGS
4.4.1.2. THERAPEUTICS
MARKET BY DISEASE STAGE
4.4.1.3. THERAPEUTICS
MARKET BY GENERIC AND BRANDED
4.4.1.4. DIAGNOSTICS
MARKET BY TYPE
4.4.2. COUNTRY
ANALYSIS
4.4.2.1. BRAZIL
4.4.2.2. MEXICO
4.4.2.3. REST
OF LATIN AMERICA
4.5. MIDDLE
EAST AND AFRICA
4.5.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.5.1.1. THERAPEUTICS
MARKET BY DRUGS
4.5.1.2. THERAPEUTICS
MARKET BY DISEASE STAGE
4.5.1.3. THERAPEUTICS
MARKET BY GENERIC AND BRANDED
4.5.1.4. DIAGNOSTICS
MARKET BY TYPE
4.5.2. COUNTRY
ANALYSIS
4.5.2.1. SAUDI
ARABIA
4.5.2.2. UNITED
ARAB EMIRATES
4.5.2.3. TURKEY
4.5.2.4. SOUTH
AFRICA
4.5.2.5. REST
OF MIDDLE EAST & AFRICA
5. COMPANY
PROFILES
5.1. ALLERGAN
PLC ACQUIRED BY ABBVIE
5.2. AMARANTUS
BIOSCIENCE HOLDINGS INC
5.3. BAXTER
INTERNATIONAL INC
5.4. BIOGEN
INC
5.5. COGNOPTIX
INC
5.6. EISAI
CO LTD
5.7. ELI
LILLY & COMPANY
5.8. F
HOFFMANN LA ROCHE
5.9. GE
HEALTHCARE
5.10. JOHNSON
& JOHNSON
5.11. LUPIN
LIMITED
5.12. LUYE
PHARMA GROUP
5.13. MERCK
& CO INC
5.14. NOVARTIS
AG
5.15. PEOPLEBIO
CO
5.16. PFIZER
INC
5.17. SIEMENS
HEALTHINEERS AG
5.18. SUN
PHARMACEUTICALS INDUSTRIES LTD
5.19. TEVA
PHARMACEUTICAL INDUSTRIES LIMITED
5.20. ZYDUS
CADILA
6. RESEARCH
METHODOLOGY & SCOPE
6.1. RESEARCH
SCOPE & DELIVERABLES
6.1.1. OBJECTIVES
OF STUDY
6.1.2. SCOPE
OF STUDY
6.2. SOURCES
OF DATA
6.2.1. PRIMARY
DATA SOURCES
6.2.2. SECONDARY
DATA SOURCES
6.3. RESEARCH
METHODOLOGY
6.3.1. EVALUATION
OF PROPOSED MARKET
6.3.2. IDENTIFICATION
OF DATA SOURCES
6.3.3. ASSESSMENT
OF MARKET DETERMINANTS
6.3.4. DATA
COLLECTION
6.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: GLOBAL ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $
MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF CONTRACTS
& PARTNERSHIPS
TABLE 4: LIST OF BUSINESS
EXPANSIONS & DIVESTITURES
TABLE 5: LIST OF ACQUISITIONS
& MERGERS
TABLE 6: LIST OF NEW PRODUCT
LAUNCHES
TABLE 7: GLOBAL ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS,
2021-2028 (IN $ MILLION)
TABLE 8: GLOBAL THERAPEUTICS
MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 9: GLOBAL THERAPEUTICS
MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 10: GLOBAL THERAPEUTICS
MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 11: GLOBAL DIAGNOSTICS
MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 12: GLOBAL ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2021-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND
DIAGNOSTICS, 2021-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA
THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA
THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 17: NORTH AMERICA
THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 18: NORTH AMERICA
DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 19: EUROPE ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $
MILLION)
TABLE 20: EUROPE ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS,
2021-2028 (IN $ MILLION)
TABLE 21: EUROPE THERAPEUTICS
MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 22: EUROPE THERAPEUTICS
MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 23: EUROPE THERAPEUTICS
MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 24: EUROPE DIAGNOSTICS
MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2021-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND
DIAGNOSTICS, 2021-2028 (IN $ MILLION)
TABLE 27: ASIA-PACIFIC
THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 28: ASIA-PACIFIC
THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 29: ASIA-PACIFIC
THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 30: ASIA-PACIFIC
DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2021-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND
DIAGNOSTICS, 2021-2028 (IN $ MILLION)
TABLE 33: LATIN AMERICA
THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 34: LATIN AMERICA
THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 35: LATIN AMERICA
THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 36: LATIN AMERICA
DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND
AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS
AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)
TABLE 39: MIDDLE EAST AND
AFRICA THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)
TABLE 40: MIDDLE EAST AND
AFRICA THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)
TABLE 41: MIDDLE EAST AND
AFRICA THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)
TABLE 42: MIDDLE EAST AND
AFRICA DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
FIGURE
1: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL
OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE
2: INDUSTRY COMPONENTS
FIGURE
3: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE
FIGURE
4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2021-2028 (IN $ MILLION)
FIGURE
5: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2028 (IN $ MILLION)
FIGURE
6: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2028 (IN $ MILLION)
FIGURE
7: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2021-2028 (IN $
MILLION)
FIGURE
8: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD,
2021-2028 (IN $ MILLION)
FIGURE
9: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2028 (IN $ MILLION)
FIGURE
10: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2021-2028 (IN $ MILLION)
FIGURE
11: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2021-2028 (IN $ MILLION)
FIGURE
12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021-2028 (IN $ MILLION)
FIGURE
13: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2028 (IN $
MILLION)
FIGURE
14: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2028 (IN $
MILLION)
FIGURE
15: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2028 (IN $
MILLION)
FIGURE
16: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2028 (IN $
MILLION)
FIGURE
17: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2028 (IN $ MILLION)
FIGURE
18: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2021-2028 (IN $ MILLION)
FIGURE
19: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2028 (IN $ MILLION)
FIGURE
20: THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
2021-2028 (IN $ MILLION)
FIGURE
21: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS 2021-2028 (IN $
MILLION)
FIGURE
22: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
23: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
24: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
25: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN
$ MILLION)
FIGURE
26: RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
27: SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN
$ MILLION)
FIGURE
28: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
29: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN
$ MILLION)
FIGURE
30: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN
$ MILLION)
FIGURE
31: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN
$ MILLION)
FIGURE
32: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)
FIGURE
33: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2021-2028 (IN $ MILLION)
FIGURE
34: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2021-2028 (IN $ MILLION)
FIGURE
35: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
MARKET 2021-2028 (IN $ MILLION)
FIGURE
36: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
37: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
38: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2021-2028 (IN $ MILLION)
FIGURE
39: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2021-2028 (IN $ MILLION)
FIGURE
40: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
MARKET 2021-2028 (IN $ MILLION)
FIGURE
41: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028
(IN $ MILLION)
FIGURE
42: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2021-2028 (IN $ MILLION)
FIGURE
43: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS &
DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)